Pandemic preparedness and the future of RNA therapeutics: RNA readiness and response

“We believe we can strengthen pandemic preparedness by developing a platform technology and manufacturing infrastructure that extends beyond vaccines, so that there is worldwide R&D and manufacturing capacity to produce RNA products.”

Charlotte Barker, Commissioning Editor, Vaccine Insights, speaks with Duccio Medini, former R3 Program Director, about the RNA Readiness + Response (R3) program, which aims to democratize the manufacturing of RNA therapeutics. They explore the advances made by R3 in scalable, multi-product RNA production, and the program’s vision for widespread, accessible RNA vaccines and therapeutics, especially in the face of future pandemics.

Please enter your email to access content Read now